Title: Long-term Follow-up Results From The Phase 2 Multicenter Study Of Ublituximab (utx), A Novel Glycoengineered Anti-cd20 Mab, In Patients With Rms

被引：0
|
作者：
Fox, E. [1 ]
Shubin, R. [2 ]
Bass, A. [3 ]
Huang, D. [4 ]
Lovett-Racke, A. [5 ]
Weiss, M. S. [6 ]
Bosco, J. [6 ]
Power, S. [6 ]
Mok, K. [6 ]
Wray, S. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Arcadia Neurol Ctr, Arcadia, CA USA
[3] Neurol Ctr San Antonio, San Antonio, TX USA
[4] Ctr Multiple Sclerosis, Westerville, OH USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] TG Therapeut, New York, NY USA
[7] Hope Neurol, Knoxville, TN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P075
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [1] Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS
    Fox, Edward
    Wray, Sibyl
    Shubin, Richard
    Huang, Deren
    Bass, Ann
    Weiss, Michael
    Power, Sean
    Bosco, Jenna
    Mok, Koby
    NEUROLOGY, 2020, 94 (15)
  • [2] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Lovett-Racke, A.
    Huang, D.
    Bass, A.
    Weiss, M.
    Power, S.
    Bosco, J.
    Mok, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544
  • [3] Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS
    Fox, Edward J.
    Lovett-Racke, Amy
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Inglese, Matilde
    Cocozza, Sirio
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna A.
    Power, Sean A.
    Weiss, Michael
    Mok, Koby
    Eubanks, James L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 49 - 49
  • [4] Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).
    Fox, E.
    Lovett-Racke, A.
    Gormley, M.
    Liu, Y.
    Wray, S.
    Shubin, R.
    Petracca, M.
    Inglese, M.
    Power, S.
    Bosco, J.
    Mok, K.
    Weiss, M.
    Eubanks, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 87 - 87
  • [5] Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
    Fox, Edward
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna
    Weiss, Michael
    Power, Sean
    Mok, Koby
    Eubanks, James
    NEUROLOGY, 2019, 92 (15)
  • [6] Open Label Extension (OLE) of Phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with Relapsing forms of Multiple Sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Mok, K.
    Power, S.
    Bosco, J.
    Weiss, M.
    Eubanks, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 105 - 105
  • [7] Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
    Lovett-Racke, Amy
    Liu, Yue
    Racke, Michael
    Shubin, Richard
    Wray, Sibyl
    Su, Wendy
    Eubanks, James
    Fox, Edward
    NEUROLOGY, 2017, 88
  • [8] Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)
    Lovett-Racke, A.
    Liu, Y.
    Racke, M.
    Wray, S.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 511 - 511
  • [9] Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
    Inglese, M.
    Petracca, M.
    Cocozza, S.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 410 - 411
  • [10] Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
    Lovett-Racke, A.
    Liu, Y.
    Gormley, M.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 610
12345